CAROLINA STUDY CONFIRMS LONG-TERM CARDIOVASCULAR SAFETY OF LIGITIN TABLETS

The findings were presented June 10 at the 79th Scientific Conference of the American Diabetes Association in San Franciscothe main endpoint of the trial was that ligitinwas was not inferior to Gremetin until the first cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (3P-MACE)In the Ligletin group, the incidence of 3P-MACE was 11.8% (356), while in the Gremetin group, the incidence was 12.0% (362)In the CAROLINA ® experiment, Ligletin's overall security was consistent with previous data and no new safety signals were foundthe study of ligitin sin is the longest of all current DPP4 inhibitor cardiovascular outcome syllables, with a median duration of more than 6 yearsIn the secondary endpoint 4P-MACE (3P-MACE and instability angina hospitalization), the Ligletin group had similar results to the Gremetin group (4P-MACE-Ligretin: 13.2%, Gremetin: 13.3%)in the CAROLINA ® trial, more patients (16.0%) in the Ligletin group reached the end of secondary compound therapeutic outcomes, the therapeutic sustainability, compared to the Gremetin group (10.2%)Compared to Gremetin, ligitinshow showed similarity in the efficacy of glycated hemoglobin (HbA1c), but significantly reduced the relative risk of hypoglycemia events in patients by 77% (in the Ligletin group, 10.6% of patients experienced any hypoglycemia events, compared to 37.7% in the Gremetin group)For all types of hypoglycemia events, ligitins can consistently and significantly reduce associated risks, including severe hypoglycemia and low blood sugar events that require hospitalizationCompared to the Gremetine group, the patients in the Ligletin group also lost a moderate weight of 1.5 kgNote: The original text has a limitation